GBA Presents: House of Gummy-!

Femy is up $2.40 now, was $2.16.



Dug this up--

Evofem Biosciences now trades at around 80 cents a share, after hitting a high of $1.57 in early July. (The stock was below 40 cents before the Supreme Court ruling.) Trading volume has been extremely high as well, a sign of the increased interest from both bulls and bears.

Evofem Biosciences isn’t the only small reproductive healthcare stock that’s been on a wild ride in the past month. Femasys, which is developing what it claims will be a permanent contraceptive solution called FemBloc, is up nearly 40% since Roe v. Wade was overturned.
 
Back
Top